Patent · US Active

Serine/threonine kinase inhibitors

US10842799B2 · kind B2 · utility

1Cited by
4References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 11, 2019
Grant dateNov 24, 2020
Priority date
Expiry dateNov 11, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D513/16
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.